Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: Pivotal study update demonstrates durable responses Academic Article uri icon

Overview

MeSH Major

  • Depsipeptides
  • Lymphoma, T-Cell, Peripheral

abstract

  • Treatment with romidepsin leads to highly durable responses in a subset of patients with relapsed/refractory PTCL, with responses ongoing as long as 48 months.

publication date

  • January 23, 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4016573

Digital Object Identifier (DOI)

  • 10.1186/1756-8722-7-11

PubMed ID

  • 24456586

Additional Document Info

start page

  • 11

volume

  • 7

number

  • 1